Pharmaxis Completes Phase II clinical study with ASM8 in asthma patients
11.03.2010 - Pharmaxis Completes Phase II clinical study with ASM8 in asthma patients
Pharmaxis Ltd today announced the successful completion of a Phase IIa dose profiling study with its new anti-inflammatory agent ASM8 in patients with allergic asthma.